ADVERTISEMENT

Cipla Q4 Review - Weak India Performance; Cut Estimates By 11-12%: Motilal Oswal

Cipla Q4 Review - Weak India Performance; Cut Estimates By 11-12%: Motilal Oswal

A technician inspects vaccine vials for defects at a pharmaceutical plant in Pune. (Photographer: Sanjit Das/Bloomberg)
A technician inspects vaccine vials for defects at a pharmaceutical plant in Pune. (Photographer: Sanjit Das/Bloomberg)
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More